Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted... o RIGINAL ARTICLE Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai, MD,* Shang-Gin Wu, MD,† Yih-Leong Chang, MD,‡ Chen-Tu Wu, MD,‡ Meng-Feng Tsai, PhD,§ Pin-Fei Wei, MS,|| Chih-Hsin Yang, MD, PhD,¶ Chong-Jen Yu, MD, PhD,* Pan-Chyr Yang, MD, PhD,*# and Jin-Yuan Shih, MD, PhD* Results: of the 78 MPE samples, direct sequencing using cell-derived Introduction: Tumor tissue is often not obtainable or suitable for RNA identified L858R mutation in 42 cases, deletions in exon 19 in molecular-based epidermal growth factor receptor (EGFR) muta- 12 cases (delE746-A750 in eight cases), other types of mutations tional analysis in advanced non–small-cell lung cancer (NSCLC). in three cases, and wild-type EGFR in 21 cases. Effusion immuno- This retrospective and single-institution study was conducted to cytochemistry with these two mutant-specific antibodies exhibited evaluate the role of effusion immunocytochemistry using two EGFR a sensitivity of 71% and 88% and a specificity of 86% and 96% for mutant-specific antibodies for the detection of relevant EGFR muta- identifying predefined L858R and delE746-A750 mutations, respec - tions in NSCLC, along with the selection of candidates for first-line tively. Effusion immunocytochemistry provided a superior prediction therapy with EGFR http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology , Volume 7 (6) – Jun 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/effusion-immunocytochemistry-as-an-alternative-approach-for-the-v0hBf5ESQm

References (39)

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31824cc46b
pmid
22525557
Publisher site
See Article on Publisher Site

Abstract

o RIGINAL ARTICLE Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai, MD,* Shang-Gin Wu, MD,† Yih-Leong Chang, MD,‡ Chen-Tu Wu, MD,‡ Meng-Feng Tsai, PhD,§ Pin-Fei Wei, MS,|| Chih-Hsin Yang, MD, PhD,¶ Chong-Jen Yu, MD, PhD,* Pan-Chyr Yang, MD, PhD,*# and Jin-Yuan Shih, MD, PhD* Results: of the 78 MPE samples, direct sequencing using cell-derived Introduction: Tumor tissue is often not obtainable or suitable for RNA identified L858R mutation in 42 cases, deletions in exon 19 in molecular-based epidermal growth factor receptor (EGFR) muta- 12 cases (delE746-A750 in eight cases), other types of mutations tional analysis in advanced non–small-cell lung cancer (NSCLC). in three cases, and wild-type EGFR in 21 cases. Effusion immuno- This retrospective and single-institution study was conducted to cytochemistry with these two mutant-specific antibodies exhibited evaluate the role of effusion immunocytochemistry using two EGFR a sensitivity of 71% and 88% and a specificity of 86% and 96% for mutant-specific antibodies for the detection of relevant EGFR muta- identifying predefined L858R and delE746-A750 mutations, respec - tions in NSCLC, along with the selection of candidates for first-line tively. Effusion immunocytochemistry provided a superior prediction therapy with EGFR

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2012

There are no references for this article.